4-((R)-3-(3-fluoro-4-methanesulfonylmethylphenoxy)-1-methylpropyl)-1-(5-isopropyl-[1,2,4]oxadiazol-3-yl)piperidine | 1037776-13-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-((R)-3-(3-fluoro-4-methanesulfonylmethylphenoxy)-1-methylpropyl)-1-(5-isopropyl-[1,2,4]oxadiazol-3-yl)piperidine
• 英文别名: 3-[4-[(2R)-4-[3-fluoro-4-(methylsulfonylmethyl)phenoxy]butan-2-yl]piperidin-1-yl]-5-propan-2-yl-1,2,4-oxadiazole
• CAS: 1037776-13-8
• 化学式: C₂₂H₃₂FN₃O₄S
• 分子量: 453.578
• InChiKey: LIBBEMSOPQMPJV-MRXNPFEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  31
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  93.9
• 氢给体数：
  0
• 氢受体数：
  8

文献信息

• Piperidine GPCR Agonists
  申请人：Fyfe Matthew Colin Thor

  公开号：US20100048631A1

  公开（公告）日：2010-02-25

  Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.

  化合物公式（I）或其药学上可接受的盐是GPCR激动剂，可用于治疗肥胖症和糖尿病。
• COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2344195A2

  公开（公告）日：2011-07-20
• COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2547339A1

  公开（公告）日：2013-01-23
• Combination therapy for the treatment of diabetes and related conditions
  申请人：Mark Michael

  公开号：US20110263617A1

  公开（公告）日：2011-10-27

  The present invention relates to combinations of DPP-4 inhibitors with GPR119 agonists, as well as to the use of these combinations for treating and/or preventing metabolic diseases, particularly diabetes (especially type 2 diabetes mellitus) and conditions related thereto.
• Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
  申请人：Eickelmann Peter

  公开号：US20130109703A1

  公开（公告）日：2013-05-02

  The present invention relates to combinations of DPP-4 inhibitors with GPR119 agonists, as well as to the use of these combinations for treating and/or preventing metabolic diseases, particularly diabetes (especially type 2 diabetes mellitus) and conditions related thereto.